Syros Pharmaceuticals (NASDAQ:SYRS) received a $33.00 price objective from JMP Securities in a research note issued on Thursday. The firm currently has a “buy” rating on the stock. JMP Securities’ price target points to a potential upside of 325.26% from the stock’s current price.
A number of other research analysts have also issued reports on SYRS. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 5th. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Oppenheimer set a $26.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. HC Wainwright reiterated a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. Finally, BidaskClub lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Syros Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $20.17.
NASDAQ SYRS opened at $7.76 on Thursday. The firm has a market capitalization of $230.87 million, a price-to-earnings ratio of -3.64 and a beta of -1.96. Syros Pharmaceuticals has a one year low of $6.25 and a one year high of $15.88.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The business had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million. Equities research analysts anticipate that Syros Pharmaceuticals will post -1.85 EPS for the current year.
Institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth about $119,000. MetLife Investment Advisors LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth about $134,000. The Manufacturers Life Insurance Company increased its stake in shares of Syros Pharmaceuticals by 299.9% during the first quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock worth $168,000 after acquiring an additional 9,691 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Syros Pharmaceuticals during the second quarter worth about $177,000. Finally, Citadel Advisors LLC purchased a new stake in Syros Pharmaceuticals during the second quarter worth about $186,000. Institutional investors and hedge funds own 60.70% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
See Also: How Buying a Call Option Works
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.